Key Highlights

  • LifeMD reported telehealth Revenue of $47.3 million, down 3.5% from a year earlier, with a net loss of $7.9 million.
  • Active subscribers grew roughly 20% to about 356,000, including around 108,000 weight-management subscribers.
  • The company cut full-year 2026 guidance to revenue of $205.5-$212.5 million as it nears the end of its shift away from compounded GLP-1 medications.
  • LFMD shares have gone quiet during the transitional period defined by the shift toward branded GLP-1 therapies.

LifeMD, Inc. (NASDAQ:LFMD), a direct-to-patient telehealth company, has gone quiet in the market during a transitional period defined by its shift toward branded GLP-1 weight-management therapies. The changeover has pressured near-term results even as its subscriber base grows, leaving investors to weigh whether the reset positions LifeMD for a surprise move once the transition is behind it.

LifeMD operates virtual-care offerings across primary care, men's health and, increasingly, weight management, monetized largely through recurring subscriptions. Its weight-management Business has ridden surging Demand for GLP-1 medications, but a shift away from compounded versions toward branded therapies has reshaped the Economics and the near-term revenue trajectory.

Latest developments

In its second-quarter 2026 results, LifeMD reported telehealth revenue of $47.3 million, down 3.5% from a year earlier, and a net loss attributable to common stockholders of $7.9 million, wider than the prior year, with adjusted EBITDA swinging to a loss of about $3.5 million. Active subscribers grew roughly 20% to about 356,000, including around 108,000 weight-management subscribers, and about 84% of revenue was recurring.

The company said roughly 95% of new weight-management patients now start on branded GLP-1 therapies and that it is effectively at the end of its transition away from compounded medications. It cut full-year 2026 guidance to revenue of $205.5 to $212.5 million and adjusted EBITDA of negative $6 million to breakeven.

Financial and business position

The GLP-1 transition has lifted gross Margin in the weight-management business while pressuring revenue and profitability in the short term, a trade-off management frames as setting up healthier economics ahead. LifeMD's large recurring-subscription base provides revenue visibility, though the guidance cut signals that the near-term financial impact of the transition is larger than previously expected.

Stock-market context

LFMD shares have gone quiet, and the stock carries a strong-buy rating in the underlying data, reflecting optimism that the transition is temporary and that subscriber growth will eventually reassert itself in the financials. The surprise-move case rests on LifeMD emerging from the transition with growing revenue and improving margins; the cautionary case is that the guidance cut, widening losses and competitive intensity in telehealth weight management could keep results under pressure longer than hoped.

What investors should watch

Investors may focus on whether telehealth revenue returns to growth as the branded-GLP-1 transition completes, the trajectory of adjusted EBITDA back toward profitability, continued subscriber additions and retention, and gross-margin trends in weight management.

A Deliberate Reset Waiting on Subscriber Growth

LifeMD's transition underscores a broader tension in the telehealth weight-management boom: the explosive demand for GLP-1 therapies created a large new market, but the economics and regulatory footing of compounded versions were always more precarious than those of branded drugs. The Investment question is whether subscriber growth, up roughly 20% year over year, eventually reasserts itself in revenue and Earnings once the mix shift is complete.